The Latest Breaking News on Pharma

The Federal Trade Commission has challenged more than 100 patents drugmakers listed in the FDA’s “Orange Book"

The pharmaceutical industry, which experienced significant growth over the past years, is anticipated to remain buoyed, driven by the increasing prevalence of chronic diseases, advancements in medical technology, and rising healthcare awareness and expenditure. Given this backdrop, quality pharma stocks Voyager Therapeutics (VYGR), Sanofi (SNY), and Pacira BioSciences (PCRX), with…

Publicis Health will pay $350 million to settle charges from US states that its "predatory and deceptive marketing strategies" worsened the opioid epidemic, New York's top prosecutor said Thursday.

Biden administration says public health insurance program has made initial offers for 10 of most commonly used medicines

The Supreme Court will soon decide the fate of access for mifepristone. The fallout of a ban would be tremendous

While AbbVie (ABBV) saw a decrease in net revenues and EPS in the last reported quarter, it raised its 2023 adjusted EPS guidance range. With the company gearing up to report fourth-quarter 2023 results tomorrow, is the stock worth buying today? Keep reading.

With rising healthcare expenditure, growing need for precision medicine, innovations in biologics and gene editing, and rapid adoption of advanced technologies, the pharma industry is well-poised for significant growth and expansion. Thus, quality pharma stocks Wave Life (WVE), Teva Pharmaceuticals (TEVA), and Collegium (COLL) could be smart buys for substantial…

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

Letters: Mark Samuels on why accessing medicines, from routine to life-changing, is getting harder; Philip Clayton wonders why we don’t manufacture our own drugs

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

Pharma giant Merck (MRK) has an impressive record of surpassing analysts’ expectations in its top and bottom lines. So, is the company on track to top estimates in the upcoming earnings release? Let’s discuss some of its financials to gauge its prospects.